- Previous Close
17.94 - Open
17.86 - Bid 16.96 x --
- Ask 16.97 x --
- Day's Range
16.59 - 17.93 - 52 Week Range
6.55 - 19.69 - Volume
194,718 - Avg. Volume
199,161 - Market Cap (intraday)
829.231M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-2.08 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.20
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
synactpharma.comRecent News: SYNACT.ST
View MorePerformance Overview: SYNACT.ST
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYNACT.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYNACT.ST
View MoreValuation Measures
Market Cap
829.23M
Enterprise Value
769.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.87
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.56%
Return on Equity (ttm)
-42.22%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-82.4M
Diluted EPS (ttm)
-2.08
Balance Sheet and Cash Flow
Total Cash (mrq)
61.21M
Total Debt/Equity (mrq)
0.88%
Levered Free Cash Flow (ttm)
-63.32M